Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lucas Martin

Nurse Practitioner Orlando, FL Nurse Practitioner

NPI 1467001701 CMS profile 11009843

189 S Orange Ave, Ste 1830, Orlando, FL 32801

Open in the dashboard

General payments

$10,354

399 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lucas Martin of Orlando, FL is reported in the CMS Open Payments database as having received $10,354 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,772 87
2024 General $2,154 80
2023 General $2,080 79
2022 General $972 29
2021 General $2,376 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lucas Martin
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lucas Martin were reported at $2,772. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lucas Martin Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,376 $135 $40–$426 $132
2022 $972 $152 $48–$470 $149
2023 $2,080 $166 $54–$529 $160
2024 $2,154 $173 $55–$556 $164
2025 $2,772 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ViiV Healthcare Company $2,674 84 payments
  2. Gilead Sciences, Inc. $1,916 62 payments
  3. AbbVie, Inc. $1,461 56 payments
  4. Amgen Inc. $641 26 payments
  5. Merck Sharp & Dohme Corporation $574 26 payments
  6. Biohaven Pharmaceuticals, Inc. $372 14 payments
  7. GlaxoSmithKline, LLC. $356 8 payments
  8. Theratechnologies Inc. $295 13 payments
  9. Novo Nordisk Inc $192 12 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $176 18 payments
  11. Other $1,697 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,354 399 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $863 38 payments
  2. DOVATO $732 26 payments
  3. CABENUVA $538 14 payments
  4. PIFELTRO $534 23 payments
  5. APRETUDE Hiv $489 18 payments
  6. APRETUDE Hiv $429 14 payments
  7. NURTEC ODT $417 16 payments
  8. Otezla $383 13 payments
  9. DELSTRIGO $370 17 payments
  10. TRELEGY ELLIPTA $356 8 payments
  11. Other $5,093 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

157

Median for Nurse Practitioner: 389

Drug cost

$256,913

Median for Nurse Practitioner: $21,885

Branded share of claims

73.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Descovy Emtricitabine/Tenofov Alafenam Brand 103 $216,758
Juluca Dolutegravir/Rilpivirine Brand 12 $39,795
Diclofenac Sodium Generic 11 $227
Gabapentin Generic 19 $85
Diazepam Generic 12 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $386
$386 — —
APRETUDE
  • ViiV Healthcare Company $272
$272 — —
CABENUVA
  • ViiV Healthcare Company $268
$268 — —
VRAYLAR
  • AbbVie, Inc. $160
$160 — —
Auvelity
  • Axsome Therapeutics, Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record